Industry Growth Insights published a new data on “Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market”. The research report is titled “Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market research by Types (Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, Others), By Applications (Hospital, Clinic, Others), By Players/Companies AbbVie Inc, Celgene Corp, CTI BioPharma Corp, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, Incyte Corp, Italfarmaco SpA, JW Pharmaceutical Corp, MedImmune LLC, MEI Pharma Inc, Merck & Co Inc, Novartis AG, NS Pharma Inc, Promedior Inc, Sun Pharma Advanced Research Company Ltd”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Research Report
By Type
Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, Others
By Application
Hospital, Clinic, Others
By Companies
AbbVie Inc, Celgene Corp, CTI BioPharma Corp, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, Incyte Corp, Italfarmaco SpA, JW Pharmaceutical Corp, MedImmune LLC, MEI Pharma Inc, Merck & Co Inc, Novartis AG, NS Pharma Inc, Promedior Inc, Sun Pharma Advanced Research Company Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Report Segments:
The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market is segmented on the basis of:
Types
Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc
- Celgene Corp
- CTI BioPharma Corp
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- Incyte Corp
- Italfarmaco SpA
- JW Pharmaceutical Corp
- MedImmune LLC
- MEI Pharma Inc
- Merck & Co Inc
- Novartis AG
- NS Pharma Inc
- Promedior Inc
- Sun Pharma Advanced Research Company Ltd
 Market Overview.svg)
Highlights of The Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Durvalumab
- Givinostat
- Glasdegib
- Idelalisib
- IMG-7289
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PPV-MF is a rare, life-threatening condition that affects the myelofibrosis (a type of bone marrow disorder) in people who have polycythemia vera. PPV-MF can cause severe shortness of breath and chest pain, as well as an increased risk for heart attack and stroke. There is no known cure for PPV-MF, but treatment focuses on managing the symptoms and preventing further complications.
Some of the major players in the post-polycythemia vera myelofibrosis (ppv-mf) market are AbbVie Inc, Celgene Corp, CTI BioPharma Corp, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, Incyte Corp, Italfarmaco SpA, JW Pharmaceutical Corp, MedImmune LLC, MEI Pharma Inc, Merck & Co Inc, Novartis AG, NS Pharma Inc, Promedior Inc, Sun Pharma Advanced Research Company Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size & Forecast, 2020-2028
4.5.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Y-o-Y Growth
4.5.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Durvalumab
5.2.2 Givinostat
5.2.3 Glasdegib
5.2.4 Idelalisib
5.2.5 IMG-7289
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Durvalumab
9.6.2 Givinostat
9.6.3 Glasdegib
9.6.4 Idelalisib
9.6.5 IMG-7289
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Durvalumab
10.6.2 Givinostat
10.6.3 Glasdegib
10.6.4 Idelalisib
10.6.5 IMG-7289
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Durvalumab
11.6.2 Givinostat
11.6.3 Glasdegib
11.6.4 Idelalisib
11.6.5 IMG-7289
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Durvalumab
12.6.2 Givinostat
12.6.3 Glasdegib
12.6.4 Idelalisib
12.6.5 IMG-7289
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Durvalumab
13.6.2 Givinostat
13.6.3 Glasdegib
13.6.4 Idelalisib
13.6.5 IMG-7289
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market: Competitive Dashboard
14.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie Inc
14.3.2 Celgene Corp
14.3.3 CTI BioPharma Corp
14.3.4 F. Hoffmann-La Roche Ltd
14.3.5 Gilead Sciences Inc
14.3.6 Incyte Corp
14.3.7 Italfarmaco SpA
14.3.8 JW Pharmaceutical Corp
14.3.9 MedImmune LLC
14.3.10 MEI Pharma Inc
14.3.11 Merck & Co Inc
14.3.12 Novartis AG
14.3.13 NS Pharma Inc
14.3.14 Promedior Inc
14.3.15 Sun Pharma Advanced Research Company Ltd
